文献速递帕金森病与运动障碍

帕金森病的疾病修饰与生物标志物开发:修正还是重构?

Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?
PubMed 文献 · Neurology · 2020-02-26

本文基于Krembil帕金森病知识缺口研讨会的讨论,探讨帕金森病是一种疾病还是多种疾病,以及生物标志物和疾病修饰策略应关注病理共性还是分子亚型。文章借用乳腺癌和囊性纤维化领域的经验,讨论临床试验失败的真伪及未来方向。

要点

  • 帕金森病异质性强,混合蛋白聚集病理常见,纯α-突触核蛋白病为少数。
  • 需区分临床试验失败是假设错误还是试验设计不足。
  • 生物标志物和疾病修饰策略可修正为关注大样本病理共性或重构为聚焦分子亚型。

核心结论

  • 帕金森病可能并非单一疾病,生物标志物与疾病修饰策略需在关注病理共性与聚焦分子亚型间权衡。

研究设计与样本

  • 基于Krembil帕金森病知识缺口研讨会的专家讨论,借鉴乳腺癌和囊性纤维化领域的经验。

主要发现

  • 尸检研究显示帕金森病中混合蛋白聚集病理为规则,纯α-突触核蛋白病为例外。
  • 临床试验失败可能反映假设错误或试验设计不足,需区分真失败与假失败。

临床怎么用

  • 临床研究中需明确帕金森病亚型分类,权衡广谱与精准生物标志物策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A fundamental question in advancing Parkinson disease (PD) research is whether it represents one disorder or many. Does each genetic PD inform a common pathobiology or represent a unique entity? Do the similarities between genetic and idiopathic forms of PD outweigh the differences? If aggregates of α-synuclein in Lewy bodies and Lewy neurites are present in most (α-synucleinopathies), are they also etiopathogenically significant in each (α-synuclein pathogenesis)? Does it matter that postmortem studies in PD have demonstrated that mixed protein-aggregate pathology is the rule and pure α-synucleinopathy the exception? Should we continue to pursue convergent biomarkers that are representative of the diverse whole of PD or subtype-specific, divergent biomarkers, present in some but absent in most? Have clinical trials that failed to demonstrate efficacy of putative disease-modifying interventions been true failures (shortcomings of the hypotheses, which should be rejected) or false failures (shortcomings of the trials; hypotheses should be preserved)? Each of these questions reflects a nosologic struggle between the lumper's clinicopathologic model that embraces heterogeneity of one disease and the splitter's focus on a pathobiology-specific set of diseases. Most important, even if PD is not a single disorder, can advances in biomarkers and disease modification be revised to concentrate on pathologic commonalities in large, clinically defined populations? Or should our efforts be reconstructed to focus on smaller subgroups of patients, distinguished by well-defined molecular characteristics, regardless of their phenotypic classification? Will our clinical trial constructs be revised to target larger and earlier, possibly even prodromal, cohorts? Or should our trials efforts be reconstructed to target smaller but molecularly defined presymptomatic or postsymptomatic cohorts? At the Krembil Knowledge Gaps in Parkinson's Disease Symposium, the tentative answers to these questions were discussed, informed by the failures and successes of the fields of breast cancer and cystic fibrosis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Espay AJ, Kalia LV, Gan-Or Z, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020. PMID: 32102975. doi:10.1212/WNL.0000000000009107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。